ADC Therapeutics SA represents a strong commitment to advancing the field of oncology by developing targeted antibody-drug conjugates (ADCs) for the treatment of various types of cancer. The company's corporate philosophy centers around innovation, scientific rigor, and patient-centricity. With a focus on ADC technology, ADC Therapeutics aims to provide effective and precise treatments that improve patients' quality of life. By harnessing the power of ADCs, the company strives to address the unmet medical needs of cancer patients and contribute to the advancement of personalized cancer therapy. ADC Therapeutics SA's dedication to cutting-edge research and development underscores its mission to revolutionize cancer treatment options.

ADC Therapeutics SA is primarily present in multiple regions and countries across the globe. These include the United States, Europe, and Asia. The company has its headquarters in Lausanne, Switzerland, but operates globally to expand its reach and deliver its innovative therapies. With a focus on the development and commercialization of antibody drug conjugates (ADCs), ADC Therapeutics SA has established a presence in key pharmaceutical markets worldwide. This allows them to collaborate with healthcare professionals and deliver their targeted therapies to address unmet medical needs.

ADC Therapeutics SA has achieved several significant milestones since its inception. The company successfully completed its initial public offering (IPO) in May 2020, raising a total of $267 million. In October 2020, ADC Therapeutics SA received accelerated approval from the U.S. Food and Drug Administration (FDA) for Loncastuximab tesirine (ZYNLONTA™), a groundbreaking antibody-drug conjugate for the treatment of relapsed or refractory large B-cell lymphoma. This approval marked a major milestone for the company and demonstrated the potential of its innovative platform technology. These achievements highlight ADC Therapeutics SA's commitment to developing novel therapies and its dedication to improving the lives of patients.

ADC Therapeutics SA is a Swiss-based biotechnology company specializing in the development of targeted antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2012, ADC Therapeutics SA has been dedicated to addressing unmet medical needs through the innovative combination of monoclonal antibodies with potent cytotoxic agents. The company's extensive research capabilities and expertise have led to the development of a robust pipeline of ADC candidates, targeting various solid tumors and hematological malignancies. ADC Therapeutics SA is committed to advancing the field of oncology and improving patient outcomes through the development of novel ADC therapies.

The main competitors of ADC Therapeutics SA in the market include other leading companies in the field of antibody-drug conjugates (ADCs) and the broader oncology drug market. Some notable competitors include Seattle Genetics Inc., Immunomedics Inc., and ImmunoGen Inc. These companies are also focused on developing and commercializing innovative ADC therapies for the treatment of various types of cancer. ADC Therapeutics SA strives to differentiate itself by leveraging its proprietary Pyrrolobenzodiazepine (PBD) technology platform, which offers distinct advantages in terms of enhanced potency and tumor-targeted drug delivery.

ADC Therapeutics SA is primarily active in the biotechnology industry.

ADC Therapeutics SA is a biotechnology company focused on the development of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary technology platform to develop targeted therapies that combine monoclonal antibodies with highly potent cytotoxic agents. By precisely delivering these cytotoxic agents to cancer cells, ADC Therapeutics aims to improve treatment outcomes while minimizing side effects. With a growing pipeline and collaborations with pharmaceutical partners, ADC Therapeutics SA is dedicated to advancing the field of ADCs and providing innovative solutions to patients with unmet medical needs.

ADC Therapeutics의 P/E 비율은 -2.17입니다.

ADC Therapeutics의 P/S 비율은 3.68입니다.

ADC Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 ADC Therapeutics 매출은 78.38 백만 USD입니다.

예상되는 ADC Therapeutics 이익은 -132.6 백만 USD입니다.

ADC Therapeutics SA is a biopharmaceutical company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of cancer. ADC Therapeutics believes that ADCs have the potential to significantly improve the efficacy and safety of cancer treatments.

ADC Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

ADC Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

ADC Therapeutics의 ISIN은 CH0499880968입니다.

ADC Therapeutics의 WKN은 A2PSR8입니다.

ADC Therapeutics의 티커는 ADCT입니다.

지난 12개월 동안 ADC Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 ADC Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

ADC Therapeutics의 현재 배당 수익률은 입니다.

ADC Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

ADC Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

ADC Therapeutics은 '건강' 섹터에 속합니다.

ADC Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 ADC Therapeutics는 0 USD를 배당금으로 지급했습니다.

ADC Therapeutics의 배당금은 USD에 지급됩니다.